Table 3.
Clinical and Demographic Predictors of Plasma APRIL in a Subsample of Patients with SCZ, BIP, and MDD (n = 668)
| Covariates | Standardized Coefficients (Beta) | t | P-value | Adjusted R2 |
|---|---|---|---|---|
| Age | −0.04 | −0.90 | .37 | 0.007 |
| Sex | 0.03 | 1.65 | .10 | |
| Ethnicity | 0.05 | 1.39 | .17 | |
| BMI | 0.04 | 1.05 | .29 | |
| hsCRP | −0.01 | −0.35 | .73 | |
| Smoking status | −0.02 | −0.46 | .65 | |
| PANSS positive | −0.09 | −2.40 | .017* | |
| PANSS negative | −0.01 | −0.30 | .77 | |
| Antipsychotics (DDD) | 0.06 | 1.51 | .13 |
SCZ, schizophrenia and other nonaffective psychotic disorders; BIP, bipolar spectrum disorder; MDD, major depressive disorder. *P < .05. Stepwise regression analysis was employed; Plasma APRIL, a prroliferation-inducing ligand; Ethnicity, European ethnicity in percent; BMI, body-mass-index, weight/(height)2, (kg/m2); Plasma hsCRP, high sensitivity C-reactive protein; antipsychotics (DDD), prescribed antipsychotics, number of defined daily doses. Smoking status (yes/no), PANSS positive, Positive and Negative Syndrome Scale, positive subscale. PANSS negative, Positive and Negative Syndrome Scale, negative subscale.